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ABSTRACT
Introduction: Brentuximab vedotin (BV)-CHP
is the new standard regimen for first-line treat-
ment of systemic anaplastic large cell lym-
phoma (sALCL). We undertook a retrospective
analysis of consecutive patients diagnosed with
sALCL, treated in routine practice, to serve as a
benchmark analysis for comparison BV-CHP
efficacy in routine practice.
Methods: Patients aged 16 years or older with
sALCL treated in seven UK and Australian cen-
tres and from 14 additional centres from the UK
Haematological Malignancy Research Network
database (n = 214). Treatment allocation was
clinician choice and included best supportive
care (BSC). Main outcomes were time to treat-
ment failure (TTF) and overall survival (OS).Supplementary Information The online version
contains supplementary material available at https://
doi.org/10.1007/s12325-021-01764-0.
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Multivariable analysis for predictors of both TTF
and OS was also undertaken.
Results: The median age 52 years (range
16–93), 18% ECOG C 3 and 40% of cases were
ALK positive. CHOP (cyclophosphamide, adri-
amycin, vincristine, prednisolone) was
employed in 152 (71%) of patients and CHOEP
(CHOP ? etoposide) in 4% of patients. For
CHOP-treated patients overall response rate
(ORR) was 65% and complete response (CR)
47%. Only 9% of patients underwent autolo-
gous stem cell transplant (ASCT). With 57
months median follow-up, 4-year TTF and OS
were 41.2% (95% CI 33.1–49.1) and 58.9% (95%
CI 50.3–66.5) respectively. Multivariable analy-
sis showed ALK? status was independently
associated with superior TTF (HR 0.36, 95% CI
0.21–0.63) but not OS (0.44, 95% CI 0.18–1.07).
Discussion: We present a retrospective analysis
with mature follow-up of one of the largest
multicentre populations of sALCL available,
comparable to similar large retrospective stud-
ies. ALK status remains a strong predictor of
outcomes.
Conclusion: These data serve as a robust
benchmark for BV-CHP as the new standard of
care for sALCL. Similar real-world evidence with
BV-CHP will be desirable to confirm the find-
ings of ECHELON-2.
Keywords: Adcetris; Autologous stem cell
transplantation; Brentuximab vedotin; CHOEP;
CHOP
Key Summary Points
We report one of the largest observational
sALCL studies demonstrating CHOP as the
preferred treatment regimen for sALCL.
CHOP demonstrated slightly inferior
outcomes in the real-world setting when
compared to clinical trial data.
Low rates of high-dose therapy (HDT)-
ASCT performed in CR1 were observed in
ALK-negative patients with sALCL in line
with current controversy of the true
benefit of this strategy.
ALK status remains a significant and
strong predictor of outcomes in sALCL,
with a 64% reduction in the risk of death
and non-significant 56% reduction in risk
of treatment failure for ALK? patients.
We also describe the real-world outcomes
of BV in the relapse setting, which
compare unfavourably with results from
pivotal trials, suggesting a degree of
patient selection.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14495121.
INTRODUCTION
Peripheral T cell lymphomas (PTCLs) represent
10–15% of non-Hodgkin lymphomas and com-
prise 23 different entities [1]. Anaplastic large
cell lymphoma (sALCL) is a relatively rare sub-
type of T cell non-Hodgkin lymphoma [2], with
a prevalence of 12.1% among PTCLs entities [1].
sALCL is characterized by ALK protein expres-
sion in 40–50% of systemic cases [3].
Cyclophosphamide, adriamycin, vincristine,
prednisolone (CHOP) has been the standard of
care for frontline sALCL for decades, delivering
5-year overall survival (OS) rates of 70–81% for
ALK-positive cases [3–5] and 42–49% for ALK-
negative cases [4–6]. The International T cell
Project has reported results of 235 ALK-negative
patients with sALCL, describing overall
response rate (ORR) and complete response (CR)
rates of 77% and 63% respectively, median
progression free survival (PFS) of 41 months
(95% CI 17–62) and 5-year OS rate of 49% (95%
CI 35–59) [7, 8]. The addition of etoposide to
CHOP (CHOEP) has been suggested to be supe-
rior to CHOP in ALK-positive sALCL. The Nor-
dic Lymphoma Group study [9] found a 66%
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reduction in risk of death with CHOEP for ALK-
positive sALCL, in multivariable cox regression
(n = 97; HR = 0.34; P = 0.008). More recently,
the German High-Grade non-Hodgkin’s lym-
phoma Study Group (DSHNHL) replicated these
findings in ALK-positive sALCL with a 5-year OS
of 97% and a risk reduction of death of 76%
with CHOEP when compared to CHOP (HR
0.24, p = 0.002), independent of International
Prognostic Index (IPI) and age [10]. For ALK-
negative sALCL, a large, single-arm phase II
study by the Nordic Lymphoma Group showed
an overall response rate of 82% with CHOEP-14
with 72% of patients undergoing autologous
stem cell transplantation. The 5-year PFS and
OS were 44% and 51% respectively [11].
More intensive approaches have also been
evaluated for sALCL with no significant
improvements to the historical CHOP results. A
phase II trial reported hyperCVIDD/MA (cy-
clophosphamide, pegylated doxorubicin, vin-
cristine, dexamethasone alternating with high-
dose methotrexate/cytarabine) with a CR rate of
83% and 3-year PFS was 43% in ALK-negative
patients with ALCL [12].
sALCL is characterized by 100% CD30 anti-
gen cell surface receptor expression. The anti-
CD30 antibody drug conjugate, brentuximab
vedotin (BV) has transformed the treatment of
relapsed sALCL following the initial high
response rates seen in the phase 1 and 2 trial
results leading to durable remission and survival
[13, 14]. More recently, BV was investigated
within first-line therapy in the ECHELON-2 trial
(NCT01777152) [15], a global randomized
phase 3 study of BV in combination with CHP,
versus standard CHOP chemotherapy, for newly
diagnosed CD30-positive peripheral T cell lym-
phomas (PTCL). Overall a 34% reduction in the
risk of death for patients with CD30? PTCL
treated with BV-CHP and a 46% reduction in
sALCL populations led to the regulatory
approval of A-CHP by both the US Food and
Drug Administration (FDA) (for CD30? PTCL,
in 2019) and European Medicines Agency
(EMA) (for ALCL only, in 2020).
We undertook a retrospective, multicentre
study of newly diagnosed consecutive patients
with sALCL, treated prior to the approval of BV-
CHP, in order to evaluate treatment patterns
and outcomes of sALCL in routine clinical
practice, where there is a paucity of data. We
also evaluated the outcomes of patients treated
with single-agent BV for relapsed or refractory
(r/r) ALCL in this large real-world cohort.
METHODS
Consecutively diagnosed patients with sALCL
treated between October 2003 and December
2018 were retrospectively identified from insti-
tutional databases at seven haemato-oncology
centres in the UK and Australia and 14 addi-
tional centres from the UK Haematological
Malignancy Research Network database [16]
(total patients, n = 214). Inclusion criteria were
age at least 16 years old at diagnosis and his-
tological confirmation of sALCL; no central
pathology review was undertaken for this study
but all cases had undergone expert
haematopathology review and fulfilled World
Health Organization (WHO) criteria for sALCL.
Exclusion criteria included post-mortem diag-
nosis and participation in the ECHELON-2 trial.
Data on DUSP22 and TP63 by fluorescence
in situ hybridisation (FISH) were unavailable
retrospectively.
Patient baseline characteristics, first and
subsequent lines of therapy, BV use and
responses in both first-line and subsequent
therapy lines were recorded. Response assess-
ment was by CT and/or PET-CT (termed PET
hereafter) and assessed by local investigators
using standard Deauville score and Lugano
classification. Deauville scores 4–5 were con-
sidered as positive. The main outcomes of
interest were time to treatment failure (TTF) and
OS following first-line and BV treatment. TTF
was defined as the time from the start of first-
line therapy until the start of subsequent line of
therapy, death or progression. Additional out-
comemeasures included frequency of BV use for
r/r ALCL and frequency of autologous stem cell
transplant (ASCT) in first remission. No data on
secondary malignancies was collected.
TTF and OS analyses were performed using
the Kaplan–Meier method with Cox regression
and the log rank test to compare groups in both
univariable and multivariable analyses. The
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assumption of proportional hazards was
checked using the Schoenfeld residuals, and
backwards selection with a p value for inclusion
of 0.1 was used to select the final multivariable
model. Chi-squared (or Fisher’s exact) tests were
used to compare frequencies between groups.
All statistical analyses were performed using
STATA version 15.1 (STATAcorp, Texas).
Compliance with Ethics Guidelines
All patient data were anonymised at source and
treated according to the General Data Protec-
tion Regulation (GDPR) and the principles of
the declaration of Helsinki. The study was a
service evaluation project and exempt from
ethic committee approval.
RESULTS
A total of 231 cases were initially identified, of
which 17 were subsequently excluded (14 due
to participation in clinical trials and three for
post-mortem diagnosis). The final cohort
included 214 patients, the median age at diag-
nosis was 52 years (range 16–93), 135 were male
(63%) and 84 (40%) patients were ALK-positive.
Median age for ALK-positive and ALK-negative
was 35 and 61 years respectively. 35 patients
(18%) had Eastern Cooperative Oncology
Group (ECOG) performace status C 3. Baseline
patient characteristics are summarized in
Table 1 alongside the characteristics of partici-
pants of the ECHELON-2 CHOP cohort for
comparative purposes.
The majority of patients received multiagent
chemotherapy as first-line therapy (N = 191,
83%), 15 patients (7%) received palliative
treatment only and 7 patients received radio-
therapy (RT) only for localized stage disease.
Only one patient had missing data for treat-
ment. For those receiving chemotherapy, the
median number of cycles administered was 6
(range 1–8) and median lines of therapy
received was 2 (range 1–6). The most frequently
employed first-line treatment regimen was
CHOP in 152 patients (71%). CHOEP was given
to 7 patients (3%) whereas 27 (13%) received
intensified regimens (e.g. CODOX-M/IVAC,
ALCL99). The remaining five patients received
other induction regimens (CVP, GCVP [two
patients], IVE/methotrexate/DHAP, IVE/
methotrexate). Mortality rate attributed to
chemotherapy by investigators was 4% (8/191);
all of these patients had received CHOP.
Amongst 198 response-evaluable patients
(including those treated with RT alone n = 7),
ORR was 71% and CR rate was 53%. When
analysed by ALK status, ALK? patients had
markedly higher CR rates compared to ALK-
patients (ALK? 58% vs ALK- 37%, p = 0.01)
with comparable ORR (ALK? 67% vs ALK-
63%, p = 0.59). CHOP-treated patients had an
ORR of 65% and a CR rate of 47%. The seven
patients treated with CHOEP and more inten-
sive protocols had an ORR and CR rate of 91%
and 71% respectively. Twenty-three patients did
not have response evaluation, mainly because
of death from progressive disease (n = 18,
counted as non-responders) and the remainder
because of missing information (excluded).
A minority of patients received ASCT con-
solidation (N = 20; 9%), 10 of whom had
received intensified induction regimens and
nine had received CHOP. The median IPI of
these patients at baseline was 2 (Table 2). The
relatively low rate of ASCT was also seen in
younger patients in CR1; of 30 ALK-negative
patients aged less than 65 years and in CR after
initial chemotherapy, only 13 (43%) underwent
ASCT. Of the remaining seven patients who
underwent ASCT, two were older than 65 years
and five were in partial response (PR). Of note,
the relapse rate in patients undergoing ASCT
consolidation was 24.5% (95% CI 8.6–58.4), as
compared to 22.2% (95% CI 13.7–34.7) in those
potentially eligible (at least 65 years of age and
in CR after induction) but who did not undergo
ASCT. The International T cell Lymphoma
Project recently reported similar low rates of
ASCT (7%) in ALK-negative ALCL [8].
Median follow-up of was 57 months (IQR
36.3–87.2). The 4-year TTF and OS after first-line
treatment were 41.5% (95% CI 34.6–48.2
months) and 58% (95% CI 50.7–64.6 months)
respectively (Fig. 1). For the CHOP-treated
cohort (n = 152), the 4-year TTF and OS were
41.2% (95% CI 33.1–49.1) and 58.9% (95% CI
50.3–66.5) (Fig. 1). ALK-negative patients’
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Table 1 Demographic characteristics at baseline of ALCL cohorts and analysed subgroups
All patients N = 214 CHOP cohort N = 152 ECHELON-2 CHOP cohortc N = 226
Age, median (range) 52.0 (16.0–93.0) 52.0 (17.0–85.0) 58 (18.0–83.0)
Male, N (%) 135 (63.1) 94 (61.8) 151 (67)
ECOG, N (%)
0–1 129 (66.5) 94 (68.1) 179 (79)
2 30 (15.5) 23 (16.7) 47 (21)
C 3 35 (18.1) 21 (15.2) 0
Missing 20 14 0
ALK positive, N (%) 84 (40.0) 67 (45.0) 49 (22)
Missing 4 3 0
B symptoms, N (%) 109 (54.2) 77 (52.4) N/A
Missing 13 5
BM involvement, N (%) 14 (8.9) 11 (9.0) N/A
Missing 57 30
Stagea, N (%)
I 22 (11.1) 17 (11.6) 9 (4)
II 49 (24.7) 38 (26.0) 37 (16)
III 32 (16.2) 24 (16.4) 67 (30)
IV 95 (48.0) 67 (45.9) 113 (50)
Missing 16 6
C 2 extranodal sites, N (%) 57 (27.8) 42 (28.4) N/A
Missing 9 4
High LDH, N (%) 95 (54.0) 64 (49.6) N/A
Missing 38 23
IPI score, grouped, N (%)b
Low: 0–2 119 (60.7) 92 (63.9) 126 (56)
High: 3? 77 (39.3) 52 (36.1) 100 (44)
Missing 18 8 6
PIT score, grouped, N (%)b
Low: 0–1 95 (54.6) 74 (57.8) N/A
High: 2? 79 (45.4) 54 (42.2) N/A
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outcomes were inferior compared to ALK-posi-
tive with 4-year TTF 28.2% (95% CI 18.6–38.6)
and OS of 43.9% (95% CI 32.6–54.6) vs 57.6%
(95% CI 44.8–68.5) and 78.6% (95% CI
66.5–86.8), respectively (log rank p\ 0.01)
(Fig. 2). Multivariable analysis (MVA) for CHOP-
treated cohort including a range of established
clinical predictive factors (Table 3) showed that
stage III/IV disease (HR 2.39, 95% CI 1.22–4.70,
p = 0.012), raised LDH (HR 2.18 95% CI
1.15–4.11, p = 0.016) and age (10-year increase)
(HR 1.29, 95% CI 1.04–1.59, p = 0.020) were the
only factors independently associated with OS.
ALK? status was not found significant for OS
(HR 0.44, 95% CI 0.18–1.07, p = 0.071) but
retained a significant magnitude effect. ALK?
status was a s ignificantly strong predictor of
TTF (HR 0.36, 95% CI 0.21–0.63, p\0.001),
independently of stage, age and LDH. Addi-
tionally, B symptoms (HR 2.45, 95% CI
1.45–4.15, p = 0.001) and sex (HR 1.94, 95% CI
1.16–3.24, p = 011) were independently associ-
ated with TTF. Baseline demographic charac-
teristics of the complete cases included in the
MVA are shown Table 1 in the supplementary
material; there were no significant differences
between the groups.
Fifty-two patients received BV at relapse,
mostly as second-line therapy (N = 33; 63%).
The median number of BV cycles administered
was 4 (IQR 1.5–6). The ORR to BV was 49% and
the CR rate was 28%. With a median follow-up
after BV was 34 months (IRQ 21.5–50.3), 3-year
TTF and OS rates were 29.7% (95% CI
17.5–43.0) and 40.2% (95% CI 26.2–53.9)
respectively (Fig. 1 in the supplementary mate-
rial). Twelve patients were bridged to an
allogeneic SCT and seven were bridged to ASCT,
15 of these patients remained alive at data cut-
off (two allo-SCT and one ASCT patient have
died). When analysed by era, 80% of patients
diagnosed in 2013 or beyond had received BV
for r/r ALCL, as compared to only 53% of those
diagnosed before 2013.
Fifty-three patients were staged with both CT
and PET-CT, with 70% concordance between
the two imaging modalities. Ten patients were
upstaged with PET-CT, four of whom were
found to have extranodal sites not identified by
CT. Considering the 175 patients evaluable for
treatment response, 95 had PET-CT and 61 had
CT only. CR rate was 63% and 51% for PET and
CT-evaluated patients, respectively. The 3-year
TTF was 71.1% and 71.3% for PET and CT-de-
fined CR respectively.
DISCUSSION
The ECHELON-2 study results have changed
clinical practice for newly diagnosed sALCL.
Data from our study, with mature follow-up,
provides a benchmark for the performance of
CHOP-like chemotherapy for sALCL treated in
routine practice before the approval of BV-CHP.
The demonstrated beneficial effect of the BV-
CHP regimen in the trial setting is likely to be
corroborated in patients with sALCL treated
with the BV-CHP regimen in the real-world
setting.
The survival outcomes for our cohort are
comparable to data from the prospective Inter-
national T cell Lymphoma Project, which
described a 3-year PFS of 47% in ALK-negative
Table 1 continued
All patients N = 214 CHOP cohort N = 152 ECHELON-2 CHOP cohortc N = 226
Missing 40 24
ALCL anaplastic large cell lymphoma, BV brentuximab vedotin, BM bone marrow, IPI International Prognostic Index,
LDH lactate dehydrogenase, PIT Prognostic Index for T cell Lymphoma
a Stage is based on CT imaging and when available on PET/CT imaging
b Missing scores grouped if definitely low or high regardless of missing values
c For comparison
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patients with ALCL [7, 8]. Comparing our find-
ings to CHOP-treated patients in the ECHELON-
2 trial, recognizing the caveat that 32% of such
patients were of non-ALCL CD30? PTCL sub-
types, the outcomes of our cohort appeared
inferior (3-year TTF 43.8% in our cohort vs 49%
PFS in ECHELON-2). These outcomes were
observed despite our CHOP-treated cohort
being younger (52 years vs 58 years), with a
higher proportion of ALK-positive patients
(45% vs 22%) and early stage disease (stage I/II
38% vs 20%). Conversely, consistent with a real-
world cohort, our study included 18% of
patients with ECOG C 3 (not included in
ECHELON -2) which may, at least in part,
explain the inferior outcomes (Table 1). ALK
status remained as a strong predictor of TTF,
independent of age, with ALK-positivity associ-
ated with a 64% reduction in the risk of pro-
gression. Given the known association between
ALK status and age, it was of no surprise that
inclusion of age in the MVA model for OS
resulted in a reduction of the significance of
ALK status; however, we that believe the mag-
nitude of effect is still clinically significant as
there was a 66% of reduction in risk of death for
ALK-positive patients. Our results contrast with
those from a French real-world cohort [10] in
which an age cutoff of 40 years was associated
with outcomes independently of ALK status. By
treating age as a continuous variable in our
model, the risk of co-segregating age and ALK
status is better mitigated; hence, our results do
support a strong association of ALK status with
clinical outcomes. This effect was evident in our
Table 2 Demographic characteristics at baseline of ASCT






Age, median (range) 39.5
(16.0–64.0)
43 (19–63)
Male, N (%) 49 (59.8) 8 (62)
ECOG, N (%)
0–1 61 (81.3) 7 (54)
2 4 (5.3) 1 (8)
C 3 10 (13.3) 3 (23)
Missing 7 2
ALK positive, N (%) 49 (60.5) 0 (0)
Missing 1 0
B symptoms, N (%) 39 (52.0) 7 (54)
Missing 7 3 (23)
BM involvement, N
(%)
7 (11.1) 5 (38)
Missing 19 4
Stagea, N (%)
I 11 (13.9) 2 (15)
II 26 (32.9) 3 (23)
III 11 (13.9) 1 (8)
IV 31 (39.2) 6 (46)
Missing 3 1
C 2 extranodal sites,
N (%)
22 (27.8) 5 (38)
Missing 3 1
High LDH, N (%) 35 (47.9) 8 (62)
Missing 9 1
IPI score, grouped, N (%)b
Low: 0–2 60 (75.9) 7 (54)
High: 3? 15 (22.7) 4 (31)
Missing 16 2






Low: 0–1 51 (77.3) 5 (54)
High: 2? 15 (22.7) 2 (15)
Missing 16 6
a Stage based on CT and when available PET/CT
b Missing scores grouped if definitely low or high regard-
less of missing values
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model, despite differences in median age at
diagnosis between ALK? and ALK- patients.
There are no published randomized trials
comparing CHOP with other chemotherapy
approaches for newly diagnosed sALCL. Retro-
spective studies support CHOEP in this context,
the Nordic Lymphoma Group study reported
improved survival outcomes (HR 0.48, 95% CI
0.32–0.74) when compared to CHOP in sALCL
[9, 17]. The T cell lymphoma project also
reported a trend towards improved outcomes
with etoposide regimens with superior 5-year
OS (56% vs 69% for etoposide-containing regi-
mens, p = 0.05) and a trend towards improved
5-year PFS (39% vs 50% for etoposide-contain-
ing regimens, p = 0.18) [8]. However, despite
the potential benefit of CHOEP in sALCL, this
regimen confers increased risk of morbidity and
mortality compared to CHOP, particularly for
patients above 60 years of age, as reported in the
German NHL-B trial [18]. In our study, there
were insufficient numbers of CHOEP-treated
patients to analyse this aspect in depth.
Other intensified CHOP-based regimens such
as HyperCVAD [12, 19] and the CHOP-IVE-MTX
regimen (extrapolating from enteropathy-asso-
ciated T cell lymphoma protocols [20]) have
been applied in ALCL. In our cohort, aug-
mented CHOP regimens were associated with
higher CR rates, a higher rate of ASCT consoli-
dation (11/27 patients) and 4-year TTF of 55.7%
(95% CI 33.8–72.9) and OS of 74.9% (95% CI
48.1–89.3). Outcome comparisons with CHOP
were not pursued, as the baseline characteristics
of these patients were non-comparable and
numbers were small.
The role of ASCT for consolidation of first-
line therapy in sALCL is controversial [21],
although this is included as a recommenda-
tion/consideration in some guidelines [6, 22].
The ECHELON-2 study reported an ASCT rate of
22% in the CHP ? BV arm compared to 17% in
the CHOP arm, reflecting the improved activity
of BV-CHP (higher rate of CR) [15]. It is worth
bFig. 1 TTF and OS Kaplan–Meier curves of complete
cohort (a, b) and CHOP-treated cohort (c, d)
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noting that the ASCT intent in the BV-CHP arm
of the ECHELON-2 trial from non-Asian coun-
tries was 49% contrasting with 32% who actu-
ally underwent ASCT [23]. There are no
randomized studies evaluating ASCT in first
response for PTCL or sALCL. A recent multina-
tional retrospective study found no survival
advantage of ASCT consolidation as first-line
therapy in PTCL [24] with a reported rate of
ASCT consolidation of 46% for sALCL. Con-
versely, a recent US retrospective real-world
study revealed an ASCT rate of only 10%, which
is consistent with our cohort, where only 9%
underwent ASCT consolidation [19]. Interest-
ingly, ALK-negative patients with ALCL who
underwent ASCT had comparable relapse rates
to those in CR who did not. This observation
has been replicated by a number of other ret-
rospective studies, with an overall lack of clear
benefit of ASCT in first remission
[9, 11, 19, 25–27].
As for response evaluation, some studies
have established a clear predictive value of
response by PET in T cell lymphoma. A retro-
spective Japanese study (N = 36) showed that
3-year PFS rates in the positive and negative PET
patients post induction were 18% and 62%
respectively [28]. A larger study including 124
patients showed independent OS benefit of PET
response with a HR of 3.3 (95% CI 1.32–8.56)
for patients with Deauville[3 at end of treat-
ment [29]. Our results suggest that demon-
strating CR by either PET or CT is associated
with higher rates of TTF at 3 years, underlining
the positive impact of chemosensitive disease in
the outcomes of sALCL.
CONCLUSIONS
Our study provides descriptive outcomes of one
of the largest multicentre population of sALCL
available, confirming ALK-status as a strong and
independent predictor of TTF and with non-
significant but clinically relevant effect on OS.
We highlight a low uptake of ASCT consolida-
tion after frontline ALCL therapy, despite being
frequently recommended within guidelines and
expert recommendations. Our findings likely
reflect the uncertainty of evidence supporting
this approach. We also highlight the presence of
a minority of patients who received BSC from
the outset, representing a group with unmet
need, for whom novel, low-toxicity and effica-
cious agents are needed. The present results
highlight some degree of patient selection in
the pivotal BV trials in the relapsed and front-
line setting and serve as an appropriate bench-
mark for the comparison of patient outcomes
treated with frontline BV-CHP. Further research
to gather real-world evidence of BV-CHP com-
bination will be desirable.
Fig. 2 TTF and OS in CHOP-treated cohort, Kaplan–-
Meier curves stratified by ALK status
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Table 3 Univariable and multivariable analyses for OS in the CHOP-treated cohort
Complete cases (UVA) N = 92a MVA
Events/N HR (95% CI) p value HR (95% CI) p value
Age (10-year increment) 47/108 1.45 (1.21, 1.73) 0.0001 1.29 (1.04–1.59) 0.020
Sex
Male 25/65 1.00 0.24 – –
Female 22/43 1.41 (0.79, 2.51) –
ECOG
0 13/49 1.00 0.0010* – –
1 15/27 3.34 (1.6, 7.1) –
2 19/32 3.10 (1.5, 6.3) –
B symptoms
Absent 23/55 1.00 0.38 – –
Present 24/53 1.29 (0.73, 2.29) –
ALK status
Negative 39/61 1.00 \ 0.0001 1.00 0.071
Positive 8/47 0.21 (0.10, 0.45)** 0.44 (0.18, 1.07)
Stage
I–II 12/44 1.00 0.0030 1.00 0.012
III–IV 35/64 2.74 (1.41, 5.30) 2.39 (1.22, 4.70)
LDH
Normal 16/58 1.00 \ 0.0001 1.00 0.016
Raised 31/50 3.03 (1.65, 5.58) 2.18 (1.15, 4.11)
Extranodal sites
0 16/47 1.00 0.11* – –
1 17/27 2.70 (1.4, 5.4) –
2? 14/34 1.67 (0.8, 3.4) –
UVA univariable analysis, MVA multivariable analysis
*Log-rank test for trend
**Fails the assumption of proportional hazards (MVA model passes)
a Demographic characteristics of complete cases are shown in Fig. 1 in the supplementary material
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Table 4 Univariable and multivariable analyses for TTF in the CHOP-treated cohort
Complete cases (UVA) N = 108a MVA
Events/N HR (95% CI) p value HR (95% CI) p value
Age (10-year increment) 64/108 1.14 (0.99, 1.32)** 0.062 – –
Sex
Male 34/65 1.00 0.074 1.00 0.011
Female 30/43 1.57 (0.96, 2.56) 1.94 (1.16–3.24)
ECOG
0 20/49 1.00 0.0010* – –
1 20/27 2.70 (1.4, 5.1) –
2 24/32 2.56 (1.4, 4.6) –
B symptoms
Absent 27/55 1.00 0.016 1.00 0.001
Present 37/53 1.85 (1.12, 3.04) 2.45 (1.45–4.15)
ALK status
Negative 46/61 1.00 0.0020 1.00 \ 0.001
Positive 18/47 0.42 (0.24, 0.72) 0.36 (0.21–0.63)
Stage
I–II 19/44 1.00 0.0040 – –
III–IV 45/64 2.20 (1.28, 3.78) –
LDH
Normal 27/58 1.00 0.0030 – –
Raised 37/50 2.14 (1.30, 3.53) –
Extranodal sites
0 23/47 1.00 0.076* – –
1 20/27 2.18 (1.2, 4.0) –
2? 21/34 1.63 (0.9, 3.0) –
UVA univariable analysis, MVA multivariable analysis
*Log-rank test for trend
**Fails the assumption of proportional hazards (MVA model passes)
a Demographic characteristics of complete cases are shown in Fig. 1 in the supplementary material
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